Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
9MW2821 in High-Risk NMIBC
NCT06551233Phase 1Recruiting
- Sponsor
- Nanjing Drum-Tower Hospital
- Start
- Apr 2024
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs), Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of bulumtatug fuvedotin in non-muscle-invasive bladder cancer (NMIBC), sponsored by Nanjing Drum-Tower Hospital. Primary endpoints: Safety and tolerability at 12 months and Recommended Phase 2 Dose and Maximum Tolerated Dose at 12 months. Started Apr 2024; status: recruiting.
02
Drugs
bulumtatug fuvedotin
03
Conditions
non-muscle-invasive bladder cancer (NMIBC)
Beyond the preview
Go deeper on NCT06551233.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06551233.